Data / Drug companies / American Regent, Inc.
American Regent, Inc.: 72 products in the FDA NDC directory, labeler code 0517
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
American Regent, Inc. (labeler code 0517) lists 72 products in the FDA National Drug Code Directory, covering 37 finished drugs by generic name. By type: 72 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 19, 2025.
The request: Watch American Regent, Inc. (FDA labeler code 0517): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0517
- Products in commercial distribution
- 72
- Packages
- 76
- Finished drugs by generic name
- 37
- Prescription products
- 72
- Over the counter products
- 0
- Flagged as original packager
- 69 of 69 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 1
- Earliest marketing start
- September 30, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 44 | 61.1% |
| New drug applications (NDA) | 22 | 30.6% |
| Other unapproved drugs | 6 | 8.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 72 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Acetylcysteine | 4 | 15 |
| Methylene blue | 4 | 15 |
| Iron sucrose | 4 | 5 |
| Glycopyrrolate | 4 | 64 |
| Cyanocobalamin | 3 | 25 |
| Hydroxyzine hydrochloride | 3 | 51 |
| Betamethasone sodium phosphate and betamethasone acetate | 3 | 3 |
| Zinc sulfate | 3 | 7 |
| Estradiol valerate | 2 | 4 |
| Epinephrine | 2 | 32 |
| Levocarnitine | 2 | 10 |
| Water | 2 | 40 |
| Aminocaproic acid | 2 | 23 |
| Atropine sulfate | 2 | 24 |
| Ferric carboxymaltose injection | 2 | 2 |
| Fomepizole | 2 | 6 |
| Vasopressin | 2 | 15 |
| Trace elements injection 4 | 2 | 1 |
| Selenious acid | 2 | 4 |
| Olanzapine | 1 | 49 |
| Potassium phosphates | 1 | 6 |
| Hydralazine hydrochloride | 1 | 47 |
| Methylergonovine maleate | 1 | 13 |
| Paclitaxel | 1 | 20 |
| Caffeine and sodium benzoate | 1 | 1 |
| Trace elements 4 | 1 | 1 |
| Dicyclomine hydrochloride | 1 | 50 |
| Glucagon injection | 1 | 1 |
| Papaverine hydrochloride | 1 | 4 |
| Ferric carboxymaltose | 1 | 3 |
| Chlorothiazide sodium | 1 | 5 |
| Nicardipine hydrochloride | 1 | 27 |
| Potassium phosphate, monobasic potassium phosphate, dibasic | 1 | 3 |
| Nitroglycerin | 1 | 40 |
| Calcium chloride | 1 | 14 |
| Potassium phosphate | 1 | 2 |
| Droperidol | 1 | 2 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 56 | 77.8% |
| Injection | 5 | 6.9% |
| Inhalant | 4 | 5.6% |
| Injection, suspension | 3 | 4.2% |
| Injection, powder, lyophilized, for solution | 2 | 2.8% |
| Injection, powder, lyophilized, for suspension | 1 | 1.4% |
| Injection, solution, concentrate | 1 | 1.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Gvoke VialDx | 0517-2901 | Injection, solution | New drug applications (NDA) | August 19, 2025 |
| Epinephrine | 0517-3030 | Injection | Generic drugs (ANDA) | October 9, 2024 |
| Sodium Phosphates | 0517-7350 | Injection, solution | Generic drugs (ANDA) | June 21, 2024 |
| Sodium Phosphates | 0517-7315 | Injection, solution | Generic drugs (ANDA) | June 21, 2024 |
| Sodium Phosphates | 0517-7305 | Injection, solution | Generic drugs (ANDA) | June 21, 2024 |
| Potassium Phosphates | 0517-2505 | Injection, solution | Generic drugs (ANDA) | October 13, 2023 |
| Potassium Phosphates | 0517-2102 | Injection, solution | Generic drugs (ANDA) | October 13, 2023 |
| Potassium Phosphates | 0517-2051 | Injection, solution | Generic drugs (ANDA) | October 13, 2023 |
| Levocarnitine | 0517-1075 | Injection, solution | Generic drugs (ANDA) | June 21, 2023 |
| Levocarnitine | 0517-1045 | Injection, solution | Generic drugs (ANDA) | June 21, 2023 |
| Vasopressin | 0517-1030 | Injection, solution | New drug applications (NDA) | June 21, 2023 |
| Paclitaxel protein bound particles albumin bound | 0517-4300 | Injection, powder, lyophilized, for suspension | New drug applications (NDA) | May 2, 2023 |
| Epinephrine | 0517-1171 | Injection, solution | Generic drugs (ANDA) | January 31, 2023 |
| Atropine Sulfate | 0517-1004 | Injection, solution | Generic drugs (ANDA) | August 2, 2022 |
| Atropine Sulfate | 0517-1001 | Injection, solution | Generic drugs (ANDA) | August 2, 2022 |
| Injectafer | 0517-0602 | Injection, solution | New drug applications (NDA) | June 1, 2022 |
| Sterile Water | 0517-3020 | Injection, solution | Other unapproved drugs | April 22, 2022 |
| Sterile Water | 0517-3010 | Injection, solution | Other unapproved drugs | April 22, 2022 |
| Selenious Acid | 0517-6502 | Injection, solution | New drug applications (NDA) | March 28, 2022 |
| Vasopressin | 0517-1020 | Injection, solution | New drug applications (NDA) | February 3, 2022 |
| Multrys | 0517-9302 | Injection, solution | New drug applications (NDA) | September 1, 2021 |
| Injectafer | 0517-0620 | Injection, solution | New drug applications (NDA) | June 1, 2021 |
| Tralement | 0517-9305 | Injection, solution | New drug applications (NDA) | September 29, 2020 |
| Fomepizole | 0517-0710 | Injection, solution | Generic drugs (ANDA) | July 31, 2020 |
| Zinc Sulfate | 0517-6101 | Injection, solution | New drug applications (NDA) | May 18, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.